2. Membrane Transporter/Ion Channel
  3. Proton Pump Na+/K+ ATPase
  4. Tegoprazan-d6

Tegoprazan-d6  (Synonyms: CJ-12420-d6; RQ-00000004-d6)

Cat. No.: HY-17623S
Handling Instructions

Molarity Calculator

Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases.

For research use only. We do not sell to patients.

Tegoprazan-d<sub>6</sub> Chemical Structure

Tegoprazan-d6 Chemical Structure

Size Price Stock Quantity
1 mg USD 950 Get quote 3 - 4 weeks 2 - 3 weeks 2 - 3 weeks
5 mg   Get quote  
10 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Tegoprazan-d6:

Tegoprazan-d6 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases[1][2][3].
In Vitro

Tegoprazan (1.0 mM and 3.0 mM, 4 h) reduces DSS-induced colitis by maintaining high junction integrity of the epithelial mucosa in Caco-2 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tegoprazan-d6 Related Antibodies

RT-PCR[1]

Cell Line: Caco-2 cells
Concentration: 1.0 mM and 3.0 mM
Incubation Time: 4 h
Result: Protected the intestinal epithelial tight junction barrier and inhibits the increase in intestinal permeability.
In Vivo

Tegoprazan (30 mg / kg, p.o., twice daily for 5 days) alleviates the severity of dinitrobenzene sulfonic acid (DNBS)-induced reduced colon length and colonic damage, as well as protecting against DNBS-induced colon inflammation in mice colon[1].
Tegoprazan (3 mg/kg and 10 mg/kg, p.o., 5 h) inhibits basal gastric acid secretion in a dose-dependent manner[2].
Tegoprazan (0.1, 1 and 10 mg/kg, p.o.) exerts an antiulcer effect in a dose-dependent manner[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Pylorus-Ligated Rats[2]
Dosage: 3 mg/kg and 10 mg/kg
Administration: p.o., a single dose
Result: Inhibited basal gastric acid secretion in a dose-dependent manner and was effective at a single dose in Pylorus-Ligated rats.
Animal Model: Naproxen-induced acute gastric ulcer rat model[2]
Dosage: 0.1, 1 and 10 mg/kg
Administration: p.o., a single day or daily for 5 days
Result: Exerted an antiulcer effect in a dose-dependent manner and was effective at a single dose in naproxen-induced acute gastric ulcer rat model.
Animal Model: DNBS and Tegoprazan-induced rats[2]
Dosage: 30 mg/kg
Administration: p.o., twice daily for 5 days
Result: Reduced mRNA expression levels of proinflammatory cytokines, especially interleukin-17 (IL17) in DNBS and Tegoprazan-induced rats.
Molecular Weight

393.42

Formula

C20H13D6F2N3O3
Unlabeled CAS

942195-55-3
SMILES

CC1=NC2=C(C=C(C=C2N1)C(N(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)O[C@H]3CCOC4=C3C(F)=CC(F)=C4
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tegoprazan-d6 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tegoprazan-d6CJ-12420-d6 RQ-00000004-d6Proton PumpNa+/K+ ATPaseSodium potassium pumpacid blockerreversibleoral activehighly selectivegastric acid secretioncolitisInflammatory bowelInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tegoprazan-d6
Cat. No.:
HY-17623S
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.